Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 2/2010

01-06-2010 | Review

Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases

Authors: Stephanie M. Stanford, Tomas M. Mustelin, Nunzio Bottini

Published in: Seminars in Immunopathology | Issue 2/2010

Login to get access

Abstract

A relatively large number of protein tyrosine phosphatases (PTPs) are known to regulate signaling through the T cell receptor (TCR). Recent human genetics studies have shown that several of these PTPs are encoded by major autoimmunity genes. Here, we will focus on the lymphoid tyrosine phosphatase (LYP), a critical negative modulator of TCR signaling encoded by the PTPN22 gene. The functional analysis of autoimmune-associated PTPN22 genetic variants suggests that genetic variability of TCR signal transduction contributes to the pathogenesis of autoimmunity in humans.
Literature
1.
Mustelin T, Tasken K (2003) Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem J 371(Pt 1):15–27PubMedCrossRef
2.
Alonso A, Sasin J, Bottini N et al (2004) Protein tyrosine phosphatases in the human genome. Cell 117(6):699–711PubMedCrossRef
3.
Mustelin T, Alonso A, Bottini N et al (2004) Protein tyrosine phosphatases in T cell physiology. Mol Immunol 41(6–7):687–700PubMedCrossRef
4.
Kozlowski M, Mlinaric-Rascan I, Feng GS et al (1993) Expression and catalytic activity of the tyrosine phosphatase PTP1C is severely impaired in motheaten and viable motheaten mice. J Exp Med 178(6):2157–2163PubMedCrossRef
5.
6.
Koretzky GA, Picus J, Schultz T, Weiss A (1991) Tyrosine phosphatase CD45 is required for T-cell antigen receptor and CD2-mediated activation of a protein tyrosine kinase and interleukin 2 production. Proc Natl Acad Sci USA 88(6):2037–2041PubMedCrossRef
7.
Majeti R, Xu Z, Parslow TG et al (2000) An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 103(7):1059–1070PubMedCrossRef
8.
Bottini N, Musumeci L, Alonso A et al (2004) A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 36(4):337–338PubMedCrossRef
9.
The Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature 447(7145):661–678CrossRef
10.
Todd JA, Walker NM, Cooper JD et al (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39(7):857–864PubMedCrossRef
11.
Hennig BJ, Fry AE, Hirai K et al (2008) PTPRC (CD45) variation and disease association studied using single nucleotide polymorphism tagging. Tissue antigens 71(5):458–463PubMedCrossRef
12.
Julia A, Ballina J, Canete JD et al (2008) Genome-wide association study of rheumatoid arthritis in the Spanish population: KLF12 as a risk locus for rheumatoid arthritis susceptibility. Arthritis Rheum 58(8):2275–2286PubMedCrossRef
13.
Concannon P, Onengut-Gumuscu S, Todd JA et al (2008) A human type 1 diabetes susceptibility locus maps to chromosome 21q22.3. Diabetes 57(10):2858–2861PubMedCrossRef
14.
Raychaudhuri S, Thomson BP, Remmers EF et al (2009) Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 41(12):1313–1318PubMedCrossRef
15.
Carpino N, Turner S, Mekala D et al (2004) Regulation of ZAP-70 activation and TCR signaling by two related proteins, Sts-1 and Sts-2. Immunity 20(1):37–46PubMedCrossRef
16.
Irie-Sasaki J, Sasaki T, Penninger JM (2003) CD45 regulated signaling pathways. Curr Top Med Chem 3(7):783–796PubMedCrossRef
17.
Hermiston ML, Xu Z, Weiss A (2003) CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 21:107–137PubMedCrossRef
18.
Andersen JN, Jansen PG, Echwald SM et al (2004) A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. Faseb J 18(1):8–30PubMedCrossRef
19.
Matthews RJ, Bowne DB, Flores E, Thomas ML (1992) Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences. Mol Cell Biol 12(5):2396–2405PubMed
20.
Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM (1999) Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 93(6):2013–2024PubMed
21.
Cloutier JF, Veillette A (1996) Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. Embo J 15(18):4909–4918PubMed
22.
Begovich AB, Carlton VE, Honigberg LA et al (2004) A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75(2):330–337PubMedCrossRef
23.
Vang T, Congia M, Macis MD et al (2005) Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 37(12):1317–1319PubMedCrossRef
24.
Hill RJ, Zozulya S, Lu YL et al (2002) The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation. Exp Hematol 30(3):237–244PubMedCrossRef
25.
Cloutier JF, Veillette A (1999) Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 189(1):111–121PubMedCrossRef
26.
Gjorloff-Wingren A, Saxena M, Williams S, Hammi D, Mustelin T (1999) Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur J Immunol 29(12):3845–3854PubMedCrossRef
27.
Wu J, Katrekar A, Honigberg LA et al (2006) Identification of substrates of human protein-tyrosine phosphatase PTPN22. J Biol Chem 281(16):11002–11010PubMedCrossRef
28.
Gregorieff A, Cloutier JF, Veillette A (1998) Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk). J Biol Chem 273(21):13217–13222PubMedCrossRef
29.
Ghose R, Shekhtman A, Goger MJ, Ji H, Cowburn D (2001) A novel, specific interaction involving the Csk SH3 domain and its natural ligand. Nat Struct Biol 8(11):998–1004PubMedCrossRef
30.
Davidson D, Bakinowski M, Thomas ML, Horejsi V, Veillette A (2003) Phosphorylation-dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. Mol Cell Biol 23(6):2017–2028PubMedCrossRef
31.
Yu X, Sun JP, He Y et al (2007) Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases. Proc Natl Acad Sci USA 104(50):19767–19772PubMedCrossRef
32.
Liu Y, Stanford SM, Jog SP et al (2009) Regulation of lymphoid tyrosine phosphatase activity: inhibition of the catalytic domain by the proximal interdomain. Biochemistry 48(31):7525–7532PubMedCrossRef
33.
Tsai SJ, Sen U, Zhao L et al (2009) Crystal structure of the human lymphoid tyrosine phosphatase catalytic domain: insights into redox regulation. Biochemistry 48(22):4838–4845PubMedCrossRef
34.
Hasegawa K, Martin F, Huang G et al (2004) PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science (New York, NY) 303(5658):685–689
35.
Zikherman J, Hermiston M, Steiner D et al (2009) PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J Immunol 182(7):4093–4106PubMedCrossRef
36.
Rieck M, Arechiga A, Onengut-Gumuscu S et al (2007) Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 179(7):4704–4710PubMed
37.
Wu C, Orozco C, Boyer J et al (2009) BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol 10(11):R130PubMedCrossRef
38.
Kyogoku C, Langefeld CD, Ortmann WA et al (2004) Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 75(3):504–507PubMedCrossRef
39.
Smyth D, Cooper JD, Collins JE et al (2004) Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 53(11):3020–3023PubMedCrossRef
40.
Orozco G, Sanchez E, Gonzalez-Gay MA et al (2005) Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 52(1):219–224PubMedCrossRef
41.
Plenge RM, Padyukov L, Remmers EF et al (2005) Replication of putative candidate-gene associations with rheumatoid arthritis in >4, 000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 77(6):1044–1060PubMedCrossRef
42.
Skorka A, Bednarczuk T, Bar-Andziak E, Nauman J, Ploski R (2005) Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dose-dependent correlation with age of onset. Clin Endocrinol 62(6):679–682CrossRef
43.
Heward JM, Brand OJ, Barrett JC et al (2007) Association of PTPN22 haplotypes with Graves' disease. J Clin Endocrinol Metab 92(2):685–690PubMedCrossRef
44.
Velaga MR, Wilson V, Jennings CE et al (2004) The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab 89(11):5862–5865PubMedCrossRef
45.
Skinningsrud B, Husebye ES, Gervin K et al (2008) Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. Eur J Hum Genet 16(8):977–982PubMedCrossRef
46.
Canton I, Akhtar S, Gavalas NG et al (2005) A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo. Genes Immun 6(7):584–587PubMedCrossRef
47.
LaBerge GS, Bennett DC, Fain PR, Spritz RA (2008) PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not. J Invest Dermatol 128(7):1757–1762PubMedCrossRef
48.
Vandiedonck C, Capdevielle C, Giraud M et al (2006) Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol 59(2):404–407PubMedCrossRef
49.
Greve B, Hoffmann P, Illes Z et al (2009) The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis. Hum Immunol 70(7):540–542PubMedCrossRef
50.
Chuang WY, Strobel P, Belharazem D et al (2009) The PTPN22(gain-of-function)+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. Genes Immun 10(8):667–672PubMedCrossRef
51.
Gourh P, Tan FK, Assassi S et al (2006) Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 54(12):3945–3953PubMedCrossRef
52.
Bottini N, Vang T, Cucca F, Mustelin T (2006) Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 18(4):207–213PubMedCrossRef
53.
Gregersen PK, Lee HS, Batliwalla F, Begovich AB (2006) PTPN22: setting thresholds for autoimmunity. Semin Immunol 18(4):214–223PubMedCrossRef
54.
Kaufman KM, Kelly JA, Herring BJ et al (2006) Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus. Arthritis Rheum 54(8):2533–2540PubMedCrossRef
55.
Chelala C, Duchatelet S, Joffret ML et al (2007) PTPN22 R620W functional variant in type 1 diabetes and autoimmunity related traits. Diabetes 56(2):522–526PubMedCrossRef
56.
Ladner MB, Bottini N, Valdes AM, Noble JA (2005) Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes. Hum Immunol 66(1):60–64PubMedCrossRef
57.
Zheng W, She JX (2005) Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes. Diabetes 54(3):906–908PubMedCrossRef
58.
Saccucci P, Del Duca E, Rapini N et al (2008) Association between PTPN22 C1858T and type 1 diabetes: a replication in continental Italy. Tissue antigens 71(3):234–237PubMedCrossRef
59.
Kahles H, Ramos-Lopez E, Lange B et al (2005) Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population. Eur J Endocrinol 153(6):895–899PubMedCrossRef
60.
Santiago JL, Martinez A, de la Calle H et al (2007) Susceptibility to type 1 diabetes conferred by the PTPN22 C1858T polymorphism in the Spanish population. BMC Med Genet 8:54PubMedCrossRef
61.
Douroudis K, Prans E, Haller K et al (2008) Protein tyrosine phosphatase non-receptor type 22 gene variants at position 1858 are associated with type 1 and type 2 diabetes in Estonian population. Tissue antigens 72(5):425–430PubMedCrossRef
62.
Fedetz M, Matesanz F, Caro-Maldonado A et al (2006) The 1858T PTPN22 gene variant contributes to a genetic risk of type 1 diabetes in a Ukrainian population. Tissue antigens 67(5):430–433PubMedCrossRef
63.
Mori M, Yamada R, Kobayashi K, Kawaida R, Yamamoto K (2005) Ethnic differences in allele frequency of autoimmune-disease-associated SNPs. J Hum Genet 50(5):264–266PubMedCrossRef
64.
Ikegami H, Kawabata Y, Noso S, Fujisawa T, Ogihara T (2007) Genetics of type 1 diabetes in Asian and Caucasian populations. Diabetes Res Clin Pract 77(Suppl 1):S116–S121PubMedCrossRef
65.
Zhang ZH, Chen F, Zhang XL et al (2008) PTPN22 allele polymorphisms in 15 Chinese populations. Int J Immunogenet 35(6):433–437PubMedCrossRef
66.
Lee HS, Korman BD, Le JM et al (2009) Genetic risk factors for rheumatoid arthritis differ in Caucasian and Korean populations. Arthritis Rheum 60(2):364–371PubMedCrossRef
67.
McPartland JM, Norris RW, Kilpatrick CW (2007) Tempo and mode in the endocannaboinoid system. J Mol Evol 65(3):267–276PubMedCrossRef
68.
Chapman SJ, Khor CC, Vannberg FO et al (2006) PTPN22 and invasive bacterial disease. Nat Genet 38(5):499–500PubMedCrossRef
69.
Azarian M, Busson M, Rocha V et al (2008) The PTPN22 R620W polymorphism is associated with severe bacterial infections after human leukocyte antigen geno-identical haematopoietic stem-cell transplantations. Transplantation 85(12):1859–1862PubMedCrossRef
70.
Gomez LM, Anaya JM, Martin J (2005) Genetic influence of PTPN22 R620W polymorphism in tuberculosis. Hum Immunol 66(12):1242–1247PubMedCrossRef
71.
Lamsyah H, Rueda B, Baassi L et al (2009) Association of PTPN22 gene functional variants with development of pulmonary tuberculosis in Moroccan population. Tissue antigens 74(3):228–232PubMedCrossRef
72.
Criswell LA, Pfeiffer KA, Lum RF et al (2005) Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620 W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 76(4):561–571PubMedCrossRef
73.
Rueda B, Nunez C, Orozco G et al (2005) C1858T functional variant of PTPN22 gene is not associated with celiac disease genetic predisposition. Hum Immunol 66(7):848–852PubMedCrossRef
74.
Zhernakova A, Eerligh P, Wijmenga C et al (2005) Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population. Genes Immun 6(6):459–461PubMedCrossRef
75.
Lee YH, Rho YH, Choi SJ et al (2007) The PTPN22 C1858T functional polymorphism and autoimmune diseases—a meta-analysis. Rheumatology (Oxford, England) 46(1):49–56CrossRef
76.
Smyth DJ, Plagnol V, Walker NM et al (2008) Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 359(26):2767–2777PubMedCrossRef
77.
van Oene M, Wintle RF, Liu X et al (2005) Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations. Arthritis Rheum 52(7):1993–1998PubMedCrossRef
78.
Prescott NJ, Fisher SA, Onnie C et al (2005) A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population. Tissue antigens 66(4):318–320PubMedCrossRef
79.
Barrett JC, Hansoul S, Nicolae DL et al (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40(8):955–962PubMedCrossRef
80.
Baranathan V, Stanford MR, Vaughan RW et al (2007) The association of the PTPN22 620W polymorphism with Behcet's disease. Ann Rheum Dis 66(11):1531–1533PubMedCrossRef
81.
Huffmeier U, Reis A, Steffens M et al (2006) Male restricted genetic association of variant R620W in PTPN22 with psoriatic arthritis. J Invest Dermatol 126(4):932–935PubMedCrossRef
82.
Butt C, Peddle L, Greenwood C et al (2006) Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study. Arthritis Res Ther 8(1):R27PubMedCrossRef
83.
Huffmeier U, Steffens M, Burkhardt H et al (2006) Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients. J Med Genet 43(6):517–522PubMedCrossRef
84.
Smith RL, Warren RB, Eyre S et al (2008) Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. Br J Dermatol 158(5):962–968PubMedCrossRef
85.
McGonagle D, Aziz A, Dickie LJ, McDermott MF (2009) An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res 65(5 Pt 2):38R–45RPubMedCrossRef
86.
Kallberg H, Padyukov L, Plenge RM et al (2007) Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 80(5):867–875PubMedCrossRef
87.
Onengut-Gumuscu S, Ewens KG, Spielman RS, Concannon P (2004) A functional polymorphism (1858C/T) in the PTPN22 gene is linked and associated with type I diabetes in multiplex families. Genes Immun 5(8):678–680PubMedCrossRef
88.
Carlton VE, Hu X, Chokkalingam AP et al (2005) PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am J Hum Genet 77(4):567–581PubMedCrossRef
89.
Michou L, Lasbleiz S, Rat AC et al (2007) Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proc Natl Acad Sci USA 104(5):1649–1654PubMedCrossRef
90.
Zoledziewska M, Perra C, Orru V et al (2008) Further evidence of a primary, causal association of the PTPN22 620 W variant with type 1 diabetes. Diabetes 57(1):229–234PubMedCrossRef
91.
Smyth DJ, Cooper JD, Howson JM et al (2008) PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes. Diabetes 57(6):1730–1737PubMedCrossRef
92.
Orru V, Tsai SJ, Rueda B et al (2009) A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet 18(3):569–579PubMedCrossRef
93.
Kawasaki E, Awata T, Ikegami H et al (2006) Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22): association between a promoter polymorphism and type 1 diabetes in Asian populations. Am J Med Genet 140(6):586–593PubMedCrossRef
94.
Cinek O, Hradsky O, Ahmedov G et al (2007) No independent role of the -1123 G > C and +2740 A > G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations. Diabetes Res Clin Pract 76(2):297–303PubMedCrossRef
95.
Steck AK, Liu SY, McFann K et al (2006) Association of the PTPN22/LYP gene with type 1 diabetes. Pediatr Diabetes 7(5):274–278PubMedCrossRef
96.
Morgan AW, Thomson W, Martin SG et al (2009) Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. Arthritis Rheum 60(9):2565–2576PubMedCrossRef
97.
Costenbader KH, Chang SC, De Vivo I, Plenge R, Karlson EW (2008) Genetic polymorphisms in PTPN22, PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohort studies: evidence of gene-environment interactions with heavy cigarette smoking. Arthritis Res Ther 10(3):R52PubMedCrossRef
98.
Mahdi H, Fisher BA, Kallberg H et al (2009) Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet 41(12):1319–1324PubMedCrossRef
99.
Lempainen J, Vaarala O, Makela M et al (2009) Interplay between PTPN22 C1858T polymorphism and cow's milk formula exposure in type 1 diabetes. J Autoimmun 33(2):155–164PubMedCrossRef
100.
Pierer M, Kaltenhauser S, Arnold S et al (2006) Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients. Arthritis Res Ther 8(3):R75PubMedCrossRef
101.
Lie BA, Viken MK, Odegard S et al (2007) Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 66(12):1604–1609PubMedCrossRef
102.
Hermann R, Lipponen K, Kiviniemi M et al (2006) Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes. Diabetologia 49(6):1198–1208PubMedCrossRef
103.
Butty V, Campbell C, Mathis D, Benoist C (2008) Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the diabetes prevention trial-type 1 (DPT-1). Diabetes 57(9):2348–2359PubMedCrossRef
104.
Steck AK, Baschal EE, Jasinski JM, Boehm BO, Bottini N, Concannon P, Julier C, Morahan G, Noble JA, Polychronakos C, She JX, Eisenbarth GS; Type I Diabetes Genetics Consortium (2009) Rs2476601 T allele (R620W) defines high-risk PTPN22 type I diabetesassociated haplotypes with preliminary evidence for an additional protective haplotype. Genes Immun Suppl 1:S21–S26PubMedCrossRef
105.
Aarnisalo J, Treszl A, Svec P et al (2008) Reduced CD4(+)T cell activation in children with type 1 diabetes carrying the PTPN22/Lyp 620Trp variant. J Autoimmun 31(1):13–21PubMedCrossRef
106.
Lefvert AK, Zhao Y, Ramanujam R et al (2008) PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis. J Neuroimmunol 197(2):110–113PubMedCrossRef
107.
Nielsen C, Barington T, Husby S, Lillevang ST (2007) Expression of human PTPN22 alleles. Genes Immun 8(2):131–137PubMedCrossRef
108.
Zhang J, Salojin K, Delovitch TL (1998) Sequestration of CD4-associated Lck from the TCR complex may elicit T cell hyporesponsiveness in nonobese diabetic mice. J Immunol 160(3):1148–1157PubMed
109.
Buchs AE, Rapoport MJ (2000) T cell signaling and autoimmune diabetes. J Pediatr Endocrinol Metab 13(9):1549–1554PubMed
110.
Sakaguchi N, Takahashi T, Hata H et al (2003) Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426(6965):454–460PubMedCrossRef
111.
Siggs OM, Miosge LA, Yates AL et al (2007) Opposing functions of the T cell receptor kinase ZAP-70 in immunity and tolerance differentially titrate in response to nucleotide substitutions. Immunity 27(6):912–926PubMedCrossRef
112.
Hsu LY, Tan YX, Xiao Z, Malissen M, Weiss A (2009) A hypomorphic allele of ZAP-70 reveals a distinct thymic threshold for autoimmune disease versus autoimmune reactivity. J Exp Med 206(11):2527–2541PubMedCrossRef
113.
Marson A, Kretschmer K, Frampton GM et al (2007) Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445(7130):931–935PubMedCrossRef
114.
Setoguchi R, Hori S, Takahashi T, Sakaguchi S (2005) Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201(5):723–735PubMedCrossRef
115.
Yamanouchi J, Rainbow D, Serra P et al (2007) Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 39(3):329–337PubMedCrossRef
116.
Tang Q, Adams JY, Penaranda C et al (2008) Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28(5):687–697PubMedCrossRef
117.
Xie Y, Liu Y, Gong G et al (2008) Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase. Bioorg Med Chem Lett 18(9):2840–2844PubMedCrossRef
118.
Wu S, Bottini M, Rickert RC, Mustelin T, Tautz L (2009) In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation. ChemMedChem 4(3):440–444PubMedCrossRef
119.
Sfar I, Gorgi Y, Aouadi H et al (2009) The PTPN22 C1858T (R620W) functional polymorphism in kidney transplantation. Transplant Proc 41(2):657–659PubMedCrossRef
120.
Chatenoud L, Thervet E, Primo J, Bach JF (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91(1):123–127PubMedCrossRef
121.
Chatenoud L (2006) CD3-specific antibodies as promising tools to aim at immune tolerance in the clinic. Int Rev Immunol 25(3–4):215–233PubMedCrossRef
122.
Hermiston ML, Zikherman J, Tan AL et al (2009) Differential impact of the CD45 juxtamembrane wedge on central and peripheral T cell receptor responses. Proc Natl Acad Sci USA 106(2):546–551PubMedCrossRef
123.
Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A (2005) The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity 23(6):635–647PubMedCrossRef
124.
Gupta VA, Hermiston ML, Cassafer G, Daikh DI, Weiss A (2008) B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency. J Exp Med 205(12):2755–2761PubMedCrossRef
125.
Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC (1996) B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 98(11):2549–2557PubMedCrossRef
126.
Kammer GM, Perl A, Richardson BC, Tsokos GC (2002) Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum 46(5):1139–1154PubMedCrossRef
127.
Khan IU, Tsokos GC, Kammer GM (2003) Abnormal B cell signal transduction in systemic lupus erythematosus. Curr Dir Autoimmun 6:89–104PubMedCrossRef
Metadata
Title
Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases
Authors
Stephanie M. Stanford
Tomas M. Mustelin
Nunzio Bottini
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 2/2010
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-010-0201-4

Other articles of this Issue 2/2010

Seminars in Immunopathology 2/2010 Go to the issue

Review

Lymphoproliferative disorders involving T helper effector cells with defective LAT signalosomes

Review

Regulatory T cells: roles of T cell receptor for their development and function

Review

Exploring the roles of CD8+ T lymphocytes in the pathogenesis of autoimmune demyelination

Review

SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions

Review

Foxp3 positive regulatory T cells: a functional regulation by the E3 ubiquitin ligase Itch

Review

Cbl-b in T-cell activation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits